Navigation Links
Isis Pharmaceuticals Adds Two New Drugs to Development Pipeline
Date:1/6/2011

at Isis Pharmaceuticals.  "In our preclinical studies, we observed reductions in body fat, reversal of existing obesity and improved insulin sensitivity with ISIS-FGFR4Rx, making this a promising drug with an exciting therapeutic profile."

ISIS-STAT3Rx is designed to treat cancer by inhibiting the production of a gene critical for tumor cell growth and survival.  Signal transducer and activator of transcription 3 (STAT3) is over-active in a variety of cancers, including brain, lung, breast, bone, liver and multiple myeloma and promotes tumor cell growth and prevents cell death.  In preclinical studies, ISIS-STAT3Rx demonstrated antitumor activity in animal models of human cancer with an attractive safety profile.  ISIS-STAT3Rx will be evaluated in a variety of cancers where STAT3 is believed to play a key role such as liver cancers and multiple myeloma.

"Cancer is a therapeutic area in which we believe antisense drugs could have a profound treatment impact.  STAT3 is a target that is widely viewed as promising, but it is inaccessible to traditional drug approaches due to the nature of the protein and its function in the cell," said Brett P. Monia, Ph.D., Vice President, Drug Discovery and Corporate Development.  "ISIS-STAT3Rx adds to our already broad and mature cancer franchise consisting of a Phase 3 drug and three Phase 2 drugs, each with promising clinical data.  These drugs inhibit many of the processes that tumor cells use to grow, proliferate, and metastasize."

Conference Call

At 12:00 p.m. Eastern Standard Time today, January 6, Isis will conduct a live webcast conference call to discuss the new development candidates added to its pipeline and related activities.  Interested parties may listen to the call by dialing 800-295-4740 and refer to passcode "ISIS2011", or access the webcast at www.isispharm.com.  A webcast replay will be a
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Onyx Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
2. Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
3. Pier Pharmaceuticals Names Peter Letendre as Chief Executive Officer, President and Director
4. Optimer Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
5. Pittsburgh-based BIOSAFE Receives EPA Registration and Enters Into Commercialization Agreement with Union Springs Pharmaceuticals
6. Access Pharmaceuticals Raises $6.0 Million In Registered Direct Offering
7. University of Utah and Navigen Pharmaceuticals Announce a New Government Contract to Advance Slit2N for the Treatment of Hemorrhagic Fever and Anthrax Exposure
8. Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study
9. AVANIR Pharmaceuticals Announces Proposed Public Offering of Common Stock
10. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 7th Annual Healthcare Conference
11. Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... 2015 TapImmune, Inc. (OTCQB: TPIV), a clinical ... reached an agreement whereby the institutional investors will have ... provide the Company up to $4.93M in near term ... statement. Under the restructured terms and subject to certain ... which could result in a larger influx of capital ...
(Date:6/2/2015)... , June 02, 2015 Research and ... the "Bioburden Testing Market by Product , Test, ... report to their offering. The bioburden testing ... from $354.4 Million in 2014, growing at a CAGR ... basis of products, the microbial limit testing market is ...
(Date:6/2/2015)... , June 2, 2015 Meet ... Emotion Scanner. Scan & Read People. Analyze emotions and ... ART Concepts, including the very first Responsive-RPG: "The Eye: ... , , , , ... and truly affect your inner feelings - and those ...
(Date:6/2/2015)... June 2, 2015   Y-Prime, Inc ., ... BIO Exhibition 2015 in Philadelphia ... largest biotechnology gathering, allows influential decision makers from ... they can evaluate emerging technologies such as YPrime. ... in the design, implementation and management of Interactive ...
Breaking Biology Technology:TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 2TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 3Bioburden Testing Market 2015 - Global Forecasts to 2019 2ARGUS - The World's First Inner Emotion Scanner Launches on KickStarter 2ARGUS - The World's First Inner Emotion Scanner Launches on KickStarter 3YPrime at BIO Exhibition in Philadelphia and DIA in Washington DC during the month of June 2
... The secret of a successful sandcastle could aid the revival ... by Durham University. Researchers, led by experts at Durham,s ... strength of rammed earth, which is growing in popularity as ... a little water to stand up, the Durham engineers found ...
... 2 Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ... Phase 3 clinical study of fidaxomicin in patients with ... by clinical investigator, Mark A. Miller, M.D., at the ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO ) , , ...
... 2 Document sharing inefficiencies in clinical trials cost investigative ... recent online poll by IntraLinks(R), the leading provider of critical ... document-related administrative duties and repetitive requests for information as significant ... of the polling results include: , , ...
Cached Biology Technology:Secret of sandcastle construction could help revive ancient building technique, researchers say 2Secret of sandcastle construction could help revive ancient building technique, researchers say 3Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI 2Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI 3Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI 4Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI 5Document Management Inefficiencies Cost Clinical Study Sites Time, Money 2
(Date:5/21/2015)... , May 21, 2015 ... Imaging Market by Solutions (Hardware, Software, Services), by Applications ... & others), by End-Users (Military & Defense & ... MarketsandMarkets, Thermal Imaging Market is expected to grow ... by 2020, at a Compound Annual Growth Rate ...
(Date:5/20/2015)... May 20, 2015 NXT-ID, Inc. (NASDAQ: ... wholly owned subsidiary, 3D-ID LLC, a company engaged in ... for the biometrics technology portion of the recently awarded ... the Department of the Army. 3D-ID LLC ... for government, law enforcement and security agencies. ...
(Date:5/19/2015)... DUBLIN , May 19, 2015 /PRNewswire/ ... ) has announced the addition of the  ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A ... provides an in-depth analysis of the current ... introduction of gene-based tests, their working principles ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Genetic Testing Market Outlook 2018 2
... study in the September 6 issue of the Journal of ... an important ciliary protein, CEP290. The results could be applied ... Mutations in human CEP290 cause cilia-related disorders that range in ... known to cause Meckel syndrome, Joubert syndrome, and NPHPthe most ...
... bacterial cells that act in their own interests ... can actually reduce the severity of infection. ... could be exploited to treat antibiotic-resistant infections, according ... General Microbiology,s autumn meeting today. Bacteria work ...
... Society is delighted to announce its 2011 Society Fellows. ... in science, contributions to the expansion of the field ... Fellows will be honored at the Awards Ceremony during ... 7, 2011 at the Baltimore Convention Center in Baltimore, ...
Cached Biology News:Backstabbing bacteria: A new treatment for infection? 2
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
... This system uses the Adept CE 4100 ... Ultra-Fast Scanning UV/Visible detector for added flexibility and ... a trustworthy alternative to a photodiode array detection ... one detector is required for method development and ...
... number is a new product number, ... number. If showing no availability yet, ... number (E6152) or contact customer service ... diam. 11.25 6.40 in. ...
... Analysis of large numbers of samples may be ... requires minimum operator attention. System control and ... interface CE 4900. The elegant, powerful and ... XP and Windows 98 and 2000., The supplied ...
Biology Products: